Cargando...
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiological JAK2 signalling. We tested whether combining a JAK2 inhibitor with a series of serine threonine kinase inhibitors, targeti...
Gardado en:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4117552/ https://ncbi.nlm.nih.gov/pubmed/24251790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.12156 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|